Lv31
320 积分 2025-05-06 加入
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
2小时前
已完结
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
7天前
已完结
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
7天前
已完结
Drugging p53 in cancer: one protein, many targets
28天前
已完结
The origin of ovarian cancer—is it getting clearer?
28天前
已完结
Drugging p53 in cancer: one protein, many targets
3个月前
已完结
Reactivating p53 mutants selectively in patients
3个月前
已完结
Revisiting p53 as a therapeutic target: emerging clinical evidence in gynecologic oncology
3个月前
已关闭
Revisiting p53 as a therapeutic target: emerging clinical evidence in gynecologic oncology
3个月前
已关闭
Ovarian Cancer Therapy
3个月前
已完结
皖公网安备34019202002308
